Long-Acting Buprenorphine Medications as a Novel Pharmacological Option in Opioid Dependence

被引：1
|
作者：
Soyka, Michael [1 ,2 ]
机构：
[1] Med Pk Chiemseeblick, Rasthausstr 25, D-83233 Bernau Felden, Germany
[2] Psychiat Univ Klin LMU Munchen, Munich, Germany
来源：
SUCHTTHERAPIE | 2020年 / 21卷 / 01期
关键词：
opioid dependence; maintenance treatment; buprenorphine; depot; implant; SUSTAINED-RELEASE FORMULATION; FOLLOW-UP; METHADONE-MAINTENANCE; USE DISORDER; HEROIN; ADDICTION; RETENTION; MORTALITY; BLOCKADE; RBP-6000;
D O I：
10.1055/a-1064-6188
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Opioid maintenance treatment with oral methadone or sublingual buprenorphine is an established first-line treatment in opioid dependence. Both drugs must be taken daily (methadone) or at least every second day (buprenorphine). Apart from the novel subcutaneous weekly and monthly depot formulations CAM 2038 (Buvidal (R)) 2 other long-acting buprenorphine formulations may be introduced in the near future: the monthly depot formulation RBP-6000 (Sublocade (TM)) and a 6-month buprenorphine implant (Probuphine (TM)). Clininical findings of these three medications are given and possible clinical indications are discussed.
引用
收藏
页码：13 / 18
页数：6
相关论文
共 50 条
  • [11] A LONG-ACTING BUPRENORPHINE DELIVERY SYSTEM
    PONTANI, RB
    MISRA, AL
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1983, 18 (03) : 471 - 474
  • [12] DESIGN, SYNTHESIS, AND PHARMACOLOGICAL EVALUATION OF ULTRASHORT-ACTING TO LONG-ACTING OPIOID ANALGESICS
    FELDMAN, PL
    JAMES, MK
    BRACKEEN, MF
    BILOTTA, JM
    SCHUSTER, SV
    LAHEY, AP
    LUTZ, MW
    JOHNSON, MR
    LEIGHTON, HJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) : 2202 - 2208
  • [13] PHARMACOLOGICAL PROFILE OF A LONG-ACTING OPIOID ANTAGONIST, NALTREXONE PHENYL OXIME
    DEHAVEN, DL
    BROSTROM, PA
    ALLEN, JT
    FERKANY, JW
    LESKO, LJ
    MAVUNKEL, BJ
    RZESZOTARSKI, WJ
    FEDERATION PROCEEDINGS, 1987, 46 (04) : 1447 - 1447
  • [14] Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders
    Saunders, Elizabeth C.
    Moore, Sarah K.
    Walsh, Olivia
    Metcalf, Stephen A.
    Budney, Alan J.
    Scherer, Emily
    Marsch, Lisa A.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 111 : 54 - 66
  • [15] Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect
    Liu, KS
    Tzeng, JI
    Chen, YW
    Huang, KL
    Kuei, CH
    Wang, JJ
    ANESTHESIA AND ANALGESIA, 2006, 102 (05): : 1445 - 1451
  • [16] Long-acting injectable buprenorphine - 'best practice' opioid agonist therapy for Australian prisoners
    Scott, Russ
    Aboud, Andrew
    O'Gorman, Thomas
    AUSTRALASIAN PSYCHIATRY, 2022, 30 (04) : 498 - 502
  • [17] The Pharmacokinetics of Long-Acting Antipsychotic Medications
    Spanarello, Stefano
    La Ferla, Teresa
    CURRENT CLINICAL PHARMACOLOGY, 2014, 9 (03): : 310 - 317
  • [18] Stabilization of remission from opioid dependence with long-acting naltrexone implant
    Msekela, S.
    Krupitsky, E.
    Zvartau, E.
    Blokhina, E.
    Kibitov, A.
    Woody, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S63 - S63
  • [19] Buprenorphine: a potential new treatment option for opioid dependence
    Srivastava, Anita
    Kahan, Meldon
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (13) : 1835 - 1836
  • [20] Effectiveness of long-acting buprenorphine - A systematic review
    McMaster, John
    Abeysundera, Hesitha
    AUSTRALASIAN PSYCHIATRY, 2024,
12345